Individuals with coronary artery disease at a young age and features of the metabolic syndrome have an increased prothrombotic potential

Thrombosis and Haemostasis

Volumn 111, Issue 3, 2013, Pages 458-464

  Kok, Maayke G M ^a   Meijers, Joost C M ^a   Pinto Sietsma, Sara Joan ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; Hypercoagulability; Metabolic disorders; Thrombin

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THROMBIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE MONITORING; CASE CONTROL STUDY; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HEMOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERCOAGULABILITY; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL MODEL; WAIST CIRCUMFERENCE;

ATHEROSCLEROSIS; HYPERCOAGULABILITY; METABOLIC DISORDERS; THROMBIN;

ADULT; AGE OF ONSET; BLOOD COAGULATION TESTS; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROTHROMBIN; RISK FACTORS; THROMBIN; THROMBOPHILIA;

EID: 84897033658     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-07-0587     Document Type: Article

References (42)

1. Willeit P, Thompson A, Aspelund T, et al. Haemostatic factors and risk of coronary heart disease in general populations: New prospective study and updated meta-analysis. PLoS ONE 2013; 8: e55157.
2. Danesh J, Lewington S, Thompson S, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. J Am Med Assoc 2005; 294: 1799-1809.
3. Mannucci PM, Asselta R, Duga S, et al. The association of factor V Leiden with myocardial infarction is replicated in 1880 patients with premature disease. J. Thromb Haemost 2010; 8: 2116-2121.
4. Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation 2003; 107: 1117-1122.
5. Loeffen R, Spronk HMH, Ten Cate H. The impact of blood coagulability on atherosclerosis and cardiovascular disease. J. Thromb Haemost 2012; 10: 1207-1216.
6. Borissoff JI, Joosen I a, Versteylen MO, et al. Accelerated In Vivo Thrombin Formation Independently Predicts the Presence and Severity of CT Angiographic Coronary Atherosclerosis. JACC Cardiovasc Imag 2012; 5: 1201-1210.
7. Carcaillon L, Alhenc-Gelas M, Bejot Y, et al. Increased thrombin generation is associated with acute ischemic stroke but not with coronary heart disease in the elderly: the Three-City cohort study. Arterioscler Thromb Vasc Biol 2011; 31: 1445-1451.
8. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 2003; 146: 948-957.
9. Ageno W, Prandoni P, Romualdi E, et al. The metabolic syndrome and the risk of venous thrombosis: a case-control study. J Thromb Haemost 2006; 4: 1914-1918.
10. Ay C, Tengler T, Vormittag R, et al. Venous thromboembolism-a manifestation of the metabolic syndrome. Haematologica 2007; 92: 374-380.
11. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
12. Georgiou D, Budoff MJ, Kaufer E, et al. Screening patients with chest pain in the emergency department using electron beam tomography: a follow-up study. J Am Coll Cardiol 2001; 38: 105-110.
13. Hemker HC, Giesen P, AlDieri R, et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper-and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32: 249-253.
14. Spronk HMH, Dielis AWJH, De Smedt E, et al. Assessment of thrombin generation II: Validation of the Calibrated Automated Thrombogram in platelet-poor plasma in a clinical laboratory. Thromb Haemost 2008; 100: 362-364.
15. NIH Guidelines. Cholesterol-at a glance. Available at: http: //www.nhlbi.nih. gov/guidelines/cholesterol/atglance.pdf.
16. Juul K, Tybjaerg-Hansen A, Steffensen R, Kofoed S, et al. Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses. Blood 2002; 100: 3-10.
17. Ye Z, Liu EHC, Higgins JPT, et al. Articles Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66 155 cases and 91 307 controls. Lancet 2006; 367: 651-658.
18. Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. J Am Med Assoc 2005; 294: 1799-1809.
19. Giannitsis E, Siemens HJ, Mitusch R, et al. Prothrombin fragments F1+2, thrombin-antithrombin III complexes, fibrin monomers and fibrinogen in patients with coronary atherosclerosis. Int J Cardiol 1999; 68: 269-274.
20. Henareh L, Jogestrand T, Agewall S. Prothrombin fragment 1 + 2 is associated with intima media thickness of the carotid artery in patients with myocardial infarction. Thromb Res 2009; 124: 526-530.
21. Páramo J a, Orbe J, Beloqui O, et al. Prothrombin fragment 1+2 is associated with carotid intima-media thickness in subjects free of clinical cardiovascular disease. Stroke 2004; 35: 1085-1089.
22. Smid M, Dielisa WJH, Winkens M, et al. Thrombin generation in patients with a first acute myocardial infarction. J Thromb Haemost 2011; 9: 450-456.
23. Cimenti C, Mangge H, Haidl H, et al. Thrombin generation in severely obese children. J Thromb Haemost 2006; 4: 1834-1836.
24. Fritsch P, Kleber M, Rosenkranz A, et al. Haemostatic alterations in overweight children: associations between metabolic syndrome, thrombin generation, and fibrinogen levels. Atherosclerosis 2010; 212: 650-655.
25. Ay L, Kopp H-P, Brix J-M, et al. Thrombin generation in morbid obesity: significant reduction after weight loss. J Thromb Haemost 2010; 8: 759-765.
26. Sanchez C, Poggi M, Morange P-E, et al. Diet modulates endogenous thrombin generation, a biological estimate of thrombosis risk, independently of the metabolic status. Arterioscler Thromb Vasc Biol 2012; 32: 2394-2404.
27. Folsom AR, Wu KK, Davis CE, et al. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991; 91: 191-205.
28. Balleisen L, Bailey J, Epping PH, et al. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. Thromb Haemost 1985; 54: 475-479.
29. Barazzoni R, Zanetti M, Davanzo G, et al. Increased fibrinogen production in type 2 diabetic patients without detectable vascular complications: correlation with plasma glucagon concentrations. J Clin Endocrinol Metab 2000; 85: 3121-3125.
30. Morishita E, Asakura H, Jokaji H, et al. Hypercoagulability and high lipoprotein(a) levels in patients with type II diabetes mellitus. Atherosclerosis 1996; 120: 7-14.
31. Franchini M, Targher G, Montagnana M, et al. The metabolic syndrome and the risk of arterial and venous thrombosis. Thromb Res 2008; 122: 727-735.
32. Carvalho de Sousa J, Bruckert E, Giral P, et al. Coagulation factor VII and plasma triglycerides. Decreased catabolism as a possible mechanism of factor VII hyperactivity. Haemostasis 1989; 19: 125-130.
33. Sakkinen PA, Wahl P, Cushman M, et al. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000; 152: 897-907.
34. Anand SS, Yi Q, Gerstein H, et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 2003; 108: 420-425.
35. Al-Hamodi Z, Ismail IS, Saif-Ali R, et al. Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects. Cardiovasc Diabetol 2011; 10: 23.
36. Mertens I, Verrijken a, Michiels JJ, et al. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes 2006; 30: 1308-1314.
37. Angelico F, Alessandr C, Ferro D, et al. Enhanced soluble CD40L in patients with metabolic syndrome: relationship with in vivo thrombin generation. Diabetologia 2006; 49: 1169-1174
38. Sommeijer DW, MacGillavry MR, Meijers JC, et al. Anti-inflammatory and anticoagulant effects of pravastatin in patients with type 2 diabetes. Diabetes Care 2004; 27: 468-473.
39. Dielisa WJH, Castoldi E, Spronk HMH, et al. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost 2008; 6: 125-131.
40. Tchaikovski SN, Van Vliet HAAM, Thomassen MCLGD, et al. Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography. Thromb Haemost 2007; 98: 1350-1356.
41. Luddington R, Baglin T. Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition. J Thromb Haemost 2004; 2: 1954-1959.
42. Santagostino E, Mancuso ME, Tripodi A, et al. Severe haemophilia with mild bleeding phenotype: molecular characterisation and global coagulation profile. J Thromb Haemost 2010; 8: 737-43.